Sarah M Temkin1, Saroj A Fleming2, Selma Amrane2, Nicholas Schluterman3, Mishka Terplan3. 1. Department of Obstetrics, Gynecology and Reproductive Science, The University of Maryland Medical School, Baltimore, MD 21201, United States. Electronic address: temkinsm@mail.nih.gov. 2. Department of Obstetrics, Gynecology and Reproductive Science, The University of Maryland Medical School, Baltimore, MD 21201, United States. 3. Department of Epidemiology and Public Health, The University of Maryland School of Medicine, Baltimore, MD 21201, United States.
Abstract
OBJECTIVE: Women with gynecologic malignancies require specialized care. We hypothesize that a geographic disparity exists amongst patients with gynecologic malignancies and that longer distance and time traveled negatively impact completion of adjuvant therapy. METHODS: Patients with incident gynecologic malignancies at a single, urban NCI-designated cancer center were identified. Distances from the patient's home to the treating facility were calculated in miles and minutes. Demographic variables were evaluated for their impact on treatment outcomes using Chi-squared, ANOVA and Kruskal-Wallis analyses. RESULTS: One hundred and fifty consecutive patients were identified. The median distance traveled to the hospital was 16.9miles with a median travel time of 28min. The distance and time traveled were significantly different between insurance groups, with the uninsured traveling the furthest for care by distance (p=0.04) and time (p=0.03). Race, tumor site, medical comorbidities and median income at zip code were not associated with travel distance or time to the hospital. The majority of patients (87%) completed recommended initial treatment. Treatment completion was related to distance traveled with those patients living at the distance extremes (<10miles or >50miles) least likely to complete care (p<0.01). The presence of medical comorbidities (p<0.01) but not insurance status was correlated to treatment completion. CONCLUSIONS: Geographic disparities exist in women with gynecologic malignancies receiving treatment at an NCI-designated cancer center. Approaches to decreasing these disparities may include improved support for cancer patients needing assistance with travel and additional social work and psychosocial support to patients with medical co-morbidities.
OBJECTIVE:Women with gynecologic malignancies require specialized care. We hypothesize that a geographic disparity exists amongst patients with gynecologic malignancies and that longer distance and time traveled negatively impact completion of adjuvant therapy. METHODS:Patients with incident gynecologic malignancies at a single, urban NCI-designated cancer center were identified. Distances from the patient's home to the treating facility were calculated in miles and minutes. Demographic variables were evaluated for their impact on treatment outcomes using Chi-squared, ANOVA and Kruskal-Wallis analyses. RESULTS: One hundred and fifty consecutive patients were identified. The median distance traveled to the hospital was 16.9miles with a median travel time of 28min. The distance and time traveled were significantly different between insurance groups, with the uninsured traveling the furthest for care by distance (p=0.04) and time (p=0.03). Race, tumor site, medical comorbidities and median income at zip code were not associated with travel distance or time to the hospital. The majority of patients (87%) completed recommended initial treatment. Treatment completion was related to distance traveled with those patients living at the distance extremes (<10miles or >50miles) least likely to complete care (p<0.01). The presence of medical comorbidities (p<0.01) but not insurance status was correlated to treatment completion. CONCLUSIONS: Geographic disparities exist in women with gynecologic malignancies receiving treatment at an NCI-designated cancer center. Approaches to decreasing these disparities may include improved support for cancerpatients needing assistance with travel and additional social work and psychosocial support to patients with medical co-morbidities.
Authors: Michelle S Wong; David T Grande; Nandita Mitra; Archana Radhakrishnan; Charles C Branas; Katelyn R Ward; Craig E Pollack Journal: Med Care Date: 2017-09 Impact factor: 2.983
Authors: Eudocia Q Lee; Ugonma N Chukwueke; Shawn L Hervey-Jumper; John F de Groot; Jose Pablo Leone; Terri S Armstrong; Susan M Chang; David Arons; Kathy Oliver; Kay Verble; Al Musella; Nicole Willmarth; Brian M Alexander; Amanda Bates; Lisa Doherty; Evanthia Galanis; Sarah Gaffey; Thomas Halkin; Bret E Friday; Maryam Fouladi; Nancy U Lin; David Macdonald; Minesh P Mehta; Marta Penas-Prado; Michael A Vogelbaum; Solmaz Sahebjam; David Sandak; Martin van den Bent; Michael Weller; David A Reardon; Patrick Y Wen Journal: Neuro Oncol Date: 2019-09-06 Impact factor: 12.300
Authors: T Clark Powell; Sarah E Dilley; Sejong Bae; J Michael Straughn; Kenneth H Kim; Charles A Leath Journal: J Low Genit Tract Dis Date: 2018-10 Impact factor: 1.925
Authors: Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: A K Sinno; X Li; R E Thompson; E J Tanner; K L Levinson; R L Stone; S M Temkin; A N Fader; D S Chi; K Long Roche Journal: Gynecol Oncol Date: 2017-03-30 Impact factor: 5.482
Authors: David A Barrington; Sarah E Dilley; Emily E Landers; Eric D Thomas; Jonathon D Boone; J Michael Straughn; Gerald McGwin; Charles A Leath Journal: Gynecol Oncol Date: 2016-10-06 Impact factor: 5.482